Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort. Neuzillet C, et al. Among authors: le sourd s. Eur J Cancer. 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. Eur J Cancer. 2019. PMID: 30826661 Free article.
Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.
Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T, Le Sourd S, Pracht M, Manceau V, Lièvre A, Boudjema K, Garin E, Edeline J. Bourien H, et al. Among authors: le du f, le sourd s. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):669-676. doi: 10.1007/s00259-018-4199-5. Epub 2018 Oct 29. Eur J Nucl Med Mol Imaging. 2019. PMID: 30374530 Free article.
Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, Ayav A, Campillo-Gimenez B, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Boucher E, Garin E. Edeline J, et al. Among authors: le sourd s. JAMA Oncol. 2020 Jan 1;6(1):51-59. doi: 10.1001/jamaoncol.2019.3702. JAMA Oncol. 2020. PMID: 31670746 Free PMC article. Clinical Trial.
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues) Investigators; GICO (Italian Group of Cholangiocarcinoma) Investigators. Neuzillet C, et al. Among authors: le sourd s. Int J Cancer. 2020 Dec 1;147(11):3177-3188. doi: 10.1002/ijc.33146. Epub 2020 Jul 7. Int J Cancer. 2020. PMID: 32525595 Free article.
Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.
Goislard de Monsabert C, Touchefeu Y, Guiu B, Campillo-Gimenez B, Farges O, Tougeron D, Baumgaertner I, Ayav A, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Garin E, Boucher E, Edeline J. Goislard de Monsabert C, et al. Among authors: le sourd s. Curr Oncol. 2021 Nov 8;28(6):4530-4541. doi: 10.3390/curroncol28060384. Curr Oncol. 2021. PMID: 34898592 Free PMC article.
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C. Coutzac C, et al. Dig Liver Dis. 2022 Oct;54(10):1335-1341. doi: 10.1016/j.dld.2022.07.008. Epub 2022 Jul 28. Dig Liver Dis. 2022. PMID: 35907691 Free article. Clinical Trial.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
35 results